Stay updated on EPOPEX Follow-up: DBV712 in Young Children Clinical Trial

Sign up to get notified when there's something new on the EPOPEX Follow-up: DBV712 in Young Children Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the EPOPEX Follow-up: DBV712 in Young Children Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T21:32:36.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of study locations for the EPITOPE Open-label Extension Study evaluating the long-term efficacy and safety of DBV712 in peanut-allergic children.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:19.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study. The new criteria specify the inclusion of participants who completed the EPITOPE study and exclude those with generalized dermatologic diseases or severe, unstable asthma.
    Difference
    10%
    Check dated 2024-05-22T21:03:24.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:25:01.000Z thumbnail image

Stay in the know with updates to EPOPEX Follow-up: DBV712 in Young Children Clinical Trial

Enter your email address, and we'll notify you when there's something new on the EPOPEX Follow-up: DBV712 in Young Children Clinical Trial page.